Development and Validation of a Novel Fibrosis Marker in Biliary Atresia during Infancy

Objectives: Most biliary atresia (BA) patients suffer from liver fibrosis and often require liver transplantation. The aim of this study was to develop and validate a novel fibrosis marker for BA patients aged 6 (equivalent to F4) at the initial surgery survived with their native liver at 1 year of age (n=9). Conclusions: The iBALF score that was developed was a good noninvasive marker of native liver fibrosis for BA patients aged